Intermittent Preventive Treatment (IPTi) for the Prevention of Malaria and Anaemia in PNG Infants
Launched by PAPUA NEW GUINEA INSTITUTE OF MEDICAL RESEARCH · Feb 1, 2006
Trial Information
Current as of May 20, 2025
Completed
Keywords
ClinConnect Summary
Intermittent preventive treatment in infancy (IPTi) is one of the most promising recent interventions to reduce the devastating impact of malaria in early childhood. Although two African studies have provided the proof of principle, further studies are needed to address several key issues. IPTi needs additional evaluation in a variety of settings and populations, alternative drugs and treatment schedules need to be tested and the long-term effect of IPTi on risk of malaria illness through early childhood needs to be clarified.
Many of these issues are currently being addressed in a series ...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 3 months old living in the aera for the next 2 years, exlusive use of the study health facilities
- Exclusion Criteria:
- • Known chronic illness, e.g. TB, diabetes, renal failure severe malnutrition (weight-for-age (WAZ) \< 60% percentile) severe anaemia (Hb \< 5 g/dl), or permanent disability, that prevents or impedes study participation
About Papua New Guinea Institute Of Medical Research
The Papua New Guinea Institute of Medical Research (PNGIMR) is a leading biomedical research organization dedicated to improving public health through innovative scientific investigations. Established to address the unique health challenges faced by the Papua New Guinean population, PNGIMR conducts rigorous clinical trials and epidemiological studies focusing on infectious diseases, tropical medicine, and other health-related issues. With a commitment to ethical research practices and community engagement, the Institute collaborates with local and international partners to translate research findings into effective health interventions and policies, ultimately aiming to enhance the well-being of communities in Papua New Guinea and beyond.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Goroka, , Papua New Guinea
Patients applied
Trial Officials
Ivo Mueller, PhD
Principal Investigator
Papua New Guinea Institute of Medical Research
John Reeder, Prof
Principal Investigator
Papua New Guinea Institute of Medical Research
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials